Remdesivir-d<sub>4</sub>

Remdesivir-d4

CAT N°: 30905
Price:

From 414.00 351.90

Remdesivir-d4 is intended for use as an internal standard for the quantification of remdesivir (Item No. 30354) by GC- or LC-MS. Remdesivir is a prodrug form of the antiviral nucleoside analog GS-441524 (Item No. 30469).{45842,45860} Upon entry into cells, remdesivir is metabolized into a nucleoside monophosphate form, which is further metabolized to an active nucleotide triphosphate that induces RNA chain termination and inhibits viral polymerases.{52859} Remdesivir reduces viral titers in primary human airway epithelial (HAE) cells infected with Middle East respiratory syndrome coronavirus (MERS-CoV) or severe acute respiratory syndrome CoV (SARS-CoV; EC50s = 0.074 and 0.069 µM, respectively). It reduces infectious virus production in SARS-CoV-2-infected HAE cells (EC50 = 10 nM).{61140} In vivo, remdesivir (25 and 50 mg/kg) reduces lung viral titers and prevents weight loss in a mouse model of SARS-CoV infection.{45860} Remdesivir (25 mg/kg) also reduces lung viral titers and lung hemorrhage and improves pulmonary function in mice infected with a chimeric SARS-CoV encoding the SARS-CoV-2 RNA-dependent RNA polymerase (RdRP).{61140} Formulations containing remdesivir have been used in the treatment of COVID-19.

We also advise you